GILBERT DANIEL: Open Payments
NPI 1467401182 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,176 in 48 payments from 16 companies in 2025. Trend: 2023 $1,885 · 2024 $2,068 · 2025 $1,176
Food & beverage: $1,176
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 13 | $303 |
| Otsuka America Pharmaceutical, Inc. | 10 | $222 |
| Novo Nordisk Inc | 4 | $106 |
| GlaxoSmithKline, LLC. | 3 | $84 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $81 |
| Amgen Inc. | 3 | $79 |
| AstraZeneca Pharmaceuticals LP | 2 | $50 |
| ViiV Healthcare Company | 2 | $48 |
| Gilead Sciences, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $29 |
Products named: ARISTADA, REXULTI, JARDIANCE, OTEZLA, TRELEGY ELLIPTA, Wegovy, CABENUVA, AIRSUPRA.
Industry payments across DC — which companies pay providers there.
